Pharma trial needs drive Roche's $1.2bn Foundation Medicine deal
This article was originally published in Scrip
Executive Summary
Roche is to take a majority stake in molecular information and genomic analysis firm Foundation Medicine (FMI) in a move that could see it invest up to $1.18bn.